You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 15, 2026

NIVESTYM Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: NIVESTYM
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for NIVESTYM
Recent Clinical Trials for NIVESTYM

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Children's Oncology GroupPhase 2
Fred Hutchinson Cancer Research CenterPhase 2
medac GmbHPhase 2

See all NIVESTYM clinical trials

Pharmacology for NIVESTYM
Physiological EffectIncreased Myeloid Cell Production
Established Pharmacologic ClassLeukocyte Growth Factor
Chemical StructureGranulocyte Colony-Stimulating Factor
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NIVESTYM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NIVESTYM Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for NIVESTYM Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for NIVESTYM

Last updated: April 15, 2026

What is NIVESTYM?

NIVESTYM is a biosimilar of filgrastim, a granulocyte colony-stimulating factor (G-CSF). It received FDA approval on September 28, 2021, for use in neutropenia caused by chemotherapy. It is marketed by Sandoz, a Novartis division.

Market Position and Competition

NIVESTYM entered a competitive market with several established G-CSF biosimilars and originator products:

  • Neupogen (Filgrastim): Original product from Amgen, launched in 1991.
  • Zarxio (Filgrastim-sndz): First biosimilar approved in the US, launched in 2015.
  • Biological E. and others: Additional biosimilars proliferate, increasing pricing pressure.

The biosimilar market for G-CSF is projected to grow substantially. According to Evaluate Pharma, the global filgrastim market was valued at approximately $3 billion in 2021 and expected to reach $4.8 billion by 2027, growing at a CAGR of roughly 8.6% (Evaluate Pharma, 2022).

Market Dynamics

Pricing and Reimbursement

  • BIOSIMILAR pricing undercuts originator by 15-30%.
  • Payers prefer biosimilars due to cost savings, leading to reduced reimbursement rates.
  • Reimbursement policies are complex, varying by country, with some regions implementing incentives for biosimilar substitution.

Presciption Patterns

  • Physicians favor biosimilars if demonstrated bioequivalence is established.
  • Switching from originators to biosimilars accelerates market penetration.
  • Transition to biosimilars requires education and confidence-building among healthcare providers.

Regulatory Environment

  • Regulatory pathways for biosimilars vary: FDA's biosimilar approval emphasizes analytical data, clinical comparability, and manufacturing consistency.
  • Patent litigations and exclusivity periods influence market entry timing.

Manufacturing and Supply Chain

  • Sandoz has invested heavily in manufacturing capabilities since 2019, aiming to ensure supply stability.
  • Biologics' complexity demands strict quality controls, affecting margins and production costs.

Financial Trajectory

Revenue Estimates

  • 2022: Estimated sales from NIVESTYM are around $100-150 million in the US.
  • 2023-2026: With increased biosimilar penetration, sales are projected to grow at a CAGR of approximately 20-25%, reaching $500 million by 2026 based on market uptake trends and existing competitor dynamics.

Cost and Pricing Strategy

  • Sandoz's pricing strategy targets 20-25% discount to Neupogen.
  • Margins are impacted by manufacturing costs, regional reimbursement policies, and market share gains.

Market Share Projections

  • Current market share in the US biosimilar filgrastim segment approximates 10-15%, with a goal to reach 30-40% within three years.
  • Growth depends on physician acceptance, insurance reimbursement, and generic competition.

Regulatory and Market Expansion

  • Pending approval in Europe and other markets offers potential revenue streams.
  • Market entry in Canada and Australia is facilitated through mutual recognition agreements, expected within 12-24 months.

Key Challenges and Risks

  • Patent litigation by originator companies may delay market expansion.
  • Price erosion driven by new biosimilars and hospital tenders.
  • Healthcare provider skepticism over biosimilar interchangeability.

Opportunities

  • Expanding indications for filgrastim biosimilars, such as stem cell mobilization.
  • Strategic collaborations with hospital networks for preferred provider status.
  • Developing differentiated formulations (e.g., longer-acting versions).

Summary Table

Factor Details Impact
Market Size (2021) $3 billion (global filgrastim) Growing demand for biosimilars
Forecast (2027) $4.8 billion Market expansion with biosimilars' adoption
Sales 2022 ~$125 million (US) Entry-stage revenue
CAGR (2022-2026) 20-25% Revenue growth trajectory
Market Share (2023) 10-15% Current position, target 30-40%

Key Takeaways

  • NIVESTYM operates within a rapidly growing biosimilar segment driven by cost-conscious payers.
  • Revenue growth hinges on market penetration, regulatory approvals, and hospital adoption.
  • Competitive pressures from originator and biosimilar companies will shape pricing strategies.
  • Supplier reputation and manufacturing capacity are critical to supply stability and cost management.
  • Expansion into international markets presents significant revenue opportunities.

FAQs

1. What are the primary competitive advantages of NIVESTYM?
It offers cost savings over the originator, compliance with regulatory standards, and stable manufacturing from Sandoz.

2. How does NIVESTYM compare price-wise to Neupogen?
It typically costs 20-25% less, driving adoption in payers and providers seeking savings.

3. What are the main barriers to NIVESTYM’s growth?
Patent disputes, biosimilar skepticism, and hospital formulary decisions pose challenges.

4. Which regions are most promising for expansion?
Europe, Canada, and Australia represent high-potential markets with favorable regulatory pathways.

5. How will biosimilar market dynamics impact NIVESTYM’s revenue?
Market share expansion depends on biosimilar acceptance, healthcare policies, and emerging competition, influencing revenue growth.


References

  1. Evaluate Pharma. (2022). Global Biosimilar Market Forecasts.
  2. U.S. Food and Drug Administration (2021). Approval Announcement for NIVESTYM.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.